Pancreatic Cancer Research

ResearcherUniversity of Maryland, BaltimoreActive in the last 2 years

Shuai Ren

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4902-6298; OpenAlex author ID A5007569895. Sources: OpenAlex.

Their work

Papers
29 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2019: 5 papers · 2020: 4 papers · 2021: 4 papers · 2022: 2 papers · 2023: 5 papers · 2024: 4 papers · 2025: 3 papers · 2026: 2 papers

Papers 29

  1. Diagnostic performance of multislice spiral computed tomography in differentiating pancreatic acinar cell carcinoma from pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00261-026-05617-8↗
  2. Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography Co-author DOI 10.21203/rs.3.rs-10196272/v1↗
  3. Serum High-Density Lipoprotein Cholesterol Concentrations in Pancreatic Ductal Adenocarcinoma and Its Association With Histological Grade in a Chinese Populati… Co-author DOI 10.1177/10732748251316602↗
  4. Developing and validating a computed tomography radiomics strategy to predict lymph node metastasis in pancreatic cancer. Co-author DOI 10.4329/wjr.v17.i8.109373↗
  5. Diagnostic Value of Serum D-dimer, CA19-9, and CT Imaging Features in Pancreatic Ductal Adenocarcinoma and Benign Pancreatic Lesions. Co-author DOI 10.7150/jca.111548↗
  6. Multimodal Imaging-Guided Photoimmunotherapy of Pancreatic Cancer by Organosilica Nanomedicine. Co-author DOI 10.1002/adhm.202302195↗
  7. Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer. Co-author DOI 10.1016/j.medj.2024.02.012↗
  8. Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.4251/wjgo.v16.i4.1256↗
  9. Comparison between solid pseudopapillary neoplasms of the pancreas and pancreatic ductal adenocarcinoma with cystic changes using computed tomography. Co-author DOI 10.4329/wjr.v16.i6.211↗
  10. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. First author DOI 10.1002/cam4.5296↗
  11. Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/20552076231179007↗
  12. Exploring the key genetic association between chronic pancreatitis and pancreatic ductal adenocarcinoma through integrated bioinformatics. Co-author DOI 10.3389/fgene.2023.1115660↗
  13. Editorial: Novel circulating biomarkers and radiomics in pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1259070↗
  14. A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer. First author DOI 10.3390/pharmaceutics15051547↗
  15. Application of Unenhanced Computed Tomography Texture Analysis to Differentiate Pancreatic Adenosquamous Carcinoma from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11596-022-2535-2↗
  16. Erratum: Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer [Corrigendum]. Co-author DOI 10.2147/ijn.s361728↗
  17. Letter regarding "Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendoc… Co-author DOI 10.1007/s00261-020-02793-z↗
  18. Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer. Co-author DOI 10.2147/ijn.s335588↗
  19. Exogenous HMGB1 Promotes the Proliferation and Metastasis of Pancreatic Cancer Cells. First author DOI 10.3389/fmed.2021.756988↗
  20. Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.744667↗
  21. Diagnostic accuracy of unenhanced CT texture analysis to differentiate mass-forming pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-020-02506-6↗
  22. Letter regarding "Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinom… Co-author DOI 10.1016/j.ejrad.2020.109282↗
  23. Differentiating hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma based on CT texture analysis. Co-author DOI 10.1177/0284185119875023↗
  24. Computed Tomography-Based Radiomics Signature for the Preoperative Differentiation of Pancreatic Adenosquamous Carcinoma From Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.01618↗
  25. Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. Co-author DOI 10.1371/journal.pone.0211566↗
  26. Differentiation of chronic mass-forming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography. Co-author DOI 10.2147/cmar.s217033↗
  27. Pancreatic Ductal Adenocarcinoma: Machine Learning-Based Quantitative Computed Tomography Texture Analysis For Prediction Of Histopathological Grade. Co-author DOI 10.2147/cmar.s218414↗
  28. A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy. Co-author DOI 10.2217/nnm-2019-0063↗
  29. Evaluation of Texture Analysis for the Differential Diagnosis of Mass-Forming Pancreatitis From Pancreatic Ductal Adenocarcinoma on Contrast-Enhanced CT Images. Co-author DOI 10.3389/fonc.2019.01171↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhongqiu Wang · 23 shared papers, 2019–2025 · strength 4.25
  2. Yingying Cao · 10 shared papers, 2020–2026 · strength 2.12
  3. Kai Guo · 13 shared papers, 2019–2025 · strength 2.08
  4. Wenli Qiu · 7 shared papers, 2019–2026 · strength 1.11
  5. Rui Zhao · 8 shared papers, 2019–2023 · strength 1.10
  6. Lina Song · 6 shared papers, 2019–2024 · strength 1.04
  7. Rong Chen · 6 shared papers, 2019–2023 · strength 0.93
  8. Zi Wang · 2 shared papers, 2026 · strength 0.69
  9. Xiao Chen · 6 shared papers, 2019–2021 · strength 0.67
  10. Yuan Li · 2 shared papers, 2025 · strength 0.55
  11. Zipeng Lu · 3 shared papers, 2021–2023 · strength 0.48
  12. Ying Tian · 2 shared papers, 2024 · strength 0.47
  13. Yuan Li · 2 shared papers, 2023 · strength 0.36
  14. Fan Xia · 1 shared paper, 2026 · strength 0.33
  15. Jie Yu · 1 shared paper, 2026 · strength 0.33
  16. Qi Lan · 1 shared paper, 2026 · strength 0.33
  17. Huifeng Zhang · 2 shared papers, 2019–2024 · strength 0.30
  18. Zhonglan Wang · 2 shared papers, 2019–2020 · strength 0.24
  19. Sean M. Ronnekleiv‐Kelly · 1 shared paper, 2024 · strength 0.20
  20. Patrick Beard Schwartz · 1 shared paper, 2024 · strength 0.20
  21. Zhaoting Li · 1 shared paper, 2024 · strength 0.20
  22. Yu Chen · 1 shared paper, 2024 · strength 0.20
  23. Quanyin Hu · 1 shared paper, 2024 · strength 0.20
  24. Jian He · 1 shared paper, 2023 · strength 0.17
  25. Kai Zhang · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.